Renal Toxicities of Novel Agents Used for Treatment of Multiple Myeloma

Clinical journal of the American Society of Nephrology: CJASN

Rimda Wanchoo² 

[1] and..**Division of Nephrology, Department of Medicine, University of Virginia Health System, Charlottesville, Virginia..*Division of Nephrology, Hofstra Northwell School of Medicine, Great Neck, New York;*Division of Nephrology, Hofstra Northwell School of Medicine, Great Neck, New York;§Kidney Diseases Branch, National Institute of Diabetes, Digestive and Kidney Disease, National Institutes of Health, Bethesda, Maryland;¶Nephrology Division, University of Mississippi Medical Center, Jackson, Mississippi;‖Department of Medicine, Renal Service, Memorial Sloan Kettering Cancer Center and Department of Medicine, Weill Cornell Medical Center, New York, New York;†Division of Internal Medicine, Section of Nephrology, The University of Texas MD Anderson Cancer Center, Houston, Texas;‡Division of Nephrology, Wayne State University School of Medicine, Detroit, Michigan

关键词: acute renal failure;    cancer;    chronic kidney disease;    drug nephrotoxicity;    Acute Kidney Injury;    Antibodies, Monoclonal;    Coal Tar;    electrolytes;    humans;    kidney;    multiple myeloma;    Proteasome Inhibitors;    Water-Electrolyte Imbalance;   

DOI  :  10.2215/CJN.06100616

学科分类：泌尿医学

来源: American Society of Nephrology

【 摘 要 】

Survival for patients with multiple myeloma has significantly improved in the last decade in large part due to the development of proteasome inhibitors and immunomodulatory drugs. These next generation agents with novel mechanisms of action as well as targeted therapies are being used both in the preclinical and clinical settings for patients with myeloma. These agents include monoclonal antibodies, deacetylase inhibitors, kinase inhibitors, agents affecting various signaling pathways, immune check point inhibitors, and other targeted therapies. In some cases, off target effects of these therapies can lead to unanticipated effects on the kidney that can range from electrolyte disorders to AKI. In this review, we discuss the nephrotoxicities of novel agents currently in practice as well as in development for the treatment of myeloma.

【 授权许可】

CC BY